We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Microsystem Reduces Cost of Developing Ion Channel Drugs

By LabMedica International staff writers
Posted on 11 Dec 2013
Image: Schematic diagram of an ion channel. 1 - channel domains (typically four per channel), 2 - outer vestibule, 3 - selectivity filter, 4 - diameter of selectivity filter, 5 - phosphorylation site, 6 - cell membrane (Photo courtesy of Wikimedia Commons).
Image: Schematic diagram of an ion channel. 1 - channel domains (typically four per channel), 2 - outer vestibule, 3 - selectivity filter, 4 - diameter of selectivity filter, 5 - phosphorylation site, 6 - cell membrane (Photo courtesy of Wikimedia Commons).
The use of a microsystem that generates ion channels in a cell-free medium is expected to boost development of drugs that target these channels in the treatment of diseases such as cystic fibrosis, myasthenia gravis, and epilepsy.

The effect of drugs on ion channels is currently studied by electrophysiology, which measures an electric current across ion channel proteins. This, however, is a slow and expensive process that is carried out using ion channels in living cell membranes.

In a paper published in the October 18, 2013, online edition of the journal Analyst, investigators at the University of Southampton (United Kingdom) in collaboration with colleagues at the University of Quebec (Montreal, Canada) described the development of a cell-free expression mixture that allows ion channels to be inserted into stable artificial "cell membranes."

Results of the study showed that single-channel current measurements of the potassium channels KcsA and hERGS5–S6 could be obtained by direct insertion in interdroplet lipid bilayers from microliters of a cell-free expression medium.

"By putting the ion channel into an artificial membrane, we only have one type of channel, no living cells, and a relatively inexpensive method for testing for several of these types of channels at once," said senior author Dr. Maurits de Planque, lecturer in electronics and computer science at the University of Southampton. "Researchers have experimented with cell-free mixtures before, but they found that this method was not economical due to the amount of expensive biochemicals required. Our proposal to develop a new platform, which uses a couple of microliters instead of milliliters, will be a very cost-effective way of doing this, particularly when the produced channel is directly inserted in a membrane for drug testing."

Related Links:

University of Southampton
University of Quebec


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Pipette
Accumax Smart Series

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more